Contact
searchSearch
HMP Global
Login

News

News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
Benjamin Besse, MD, PhD
Conference Coverage
First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
10/21/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD,...
10/21/2024
Oncology
Benjamin Besse, MD, PhD
Conference Coverage
First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
10/21/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD,...
10/21/2024
Oncology
News
Novel EGFR x HER3 Bispecific Antibody-Drug Conjugate Shows Promise Among Heavily-Pretreated Patients With Advanced Urothelial Carcinoma
10/21/2024
A novel EGFR x HER3 bispecific ADC showed encouraging antitumor activity for heavily-pretreated advanced urothelial carcinoma.
A novel EGFR x HER3 bispecific ADC showed encouraging antitumor activity for heavily-pretreated advanced urothelial carcinoma.
A novel EGFR x HER3 bispecific...
10/21/2024
Oncology
News
Amivantamab Plus Chemotherapy Numerically Improved OS for Patients with EGFR-Mutant, Advanced NSCLC
10/21/2024
According to second interim data from the MARIPOSA-2 trial, amivantamab plus chemotherapy numerically improved the overall survival, and significantly prolonged the post-progression outcomes among patients with EGFR-mutant non-small cell lung...
According to second interim data from the MARIPOSA-2 trial, amivantamab plus chemotherapy numerically improved the overall survival, and significantly prolonged the post-progression outcomes among patients with EGFR-mutant non-small cell lung...
According to second interim data...
10/21/2024
Oncology
News
FDA Approves Osimertinib Following Chemoradiation for Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer Harboring EGFR Mutations
09/25/2024
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA...
09/25/2024
Oncology
FDA Approval
FDA Grants Approval to Amivantamab With Carboplatin and Pemetrexed for Patients With NSCLC With EGFR Exon 19 Deletions or L858R Mutations
09/20/2024
The FDA approved amivantamab plus carboplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations and disease progression on or...
The FDA approved amivantamab plus carboplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations and disease progression on or...
The FDA approved amivantamab...
09/20/2024
Oncology
Conference Coverage
Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/10/2024
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the...
09/10/2024
Oncology
Conference Coverage
Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/10/2024
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the...
09/10/2024
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use